BRD9185

• UNSPSC Description:

  BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC50 of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model[1].

• Target Antigen:

  Dihydroorotate Dehydrogenase; DNA/RNA Synthesis; Parasite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/brd9185.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1[C@@H]([C@H]([C@H]1C#N)C2=CC=C(C3=CC=C(C(C(F)(F)F)=C3)C(F)(F)F)C=C2)CO)NCCC

• Molecular Weight:

  485.42

• References & Citations:

  [1]Maetani M, et al. Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase. ACS Med Chem Lett. 2017 Feb 27;8(4):438-442.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2057420-29-6